A randomized trial of evolocumab on saphenous vein graft patency following coronary artery bypass surgery
Dr James Edelman
The study is a randomised trial looking at the impact of a Proprotein Convertase Subtilisin/Kexin Type 9 inhibitor (PCSK9i) on saphenous vein graft patency following coronary artery bypass surgery (CABG), as assessed by computed tomography angiography (CTA). The NEWTON-CABG study is an investigator-initiated study led by Principal Investigators’ Dr Subodh Verma and Dr David Mazer located in Canada. In Australia, the study will be project managed and operationalised by the Victorian Heart Institute located at Monash University.
Prof Stephen Nicholls and Prof Julian Smith will be the local Investigators for this study. Cardiothoracic surgeon, James Edelman is the local Principal investigator and patients are currently being recruited at Fiona Stanley Hospital into this study.
X-VIVO Heart Box Trial
Australian and New Zealand Multicenter Trial of Extended (6-8 Hours) Non-ischemic Heart Preservation (Nihp) of Donor Hearts for TransplantationRead More
Preserving the Endothelial Glycocalyx in Patients Undergoing Cardiopulmonary Bypass. A Prospective Randomised Interventional Pilot Study of Doxycycline and Lidocaine (Lideg)Read More
Substrate and Oxygen Persufflation of Hearts in Storage for TransplantationRead More
Substrate and Oxygen Persufflation of Hearts in Storage for Transplantation Adapted Into a Rodent ModelRead More
Prothrombinex Vs Fresh Frozen Plasma for Bleeding After Cardiopulmonary Bypass (Popcab)Read More